Oncology Billing and Coding Services
Oncology Revenue Governance Built for High-Cost, High-Risk Claims
No specialty carries more dollars per line item than oncology. Drug acquisition costs typically make up 60-80% of an oncology practice's total revenue, so a single miscoded J-code, a missed NDC number, or a lapsed prior authorization on a high-cost biologic doesn't just create a denial — it can leave the practice holding tens of thousands of dollars in drug cost with no path to reimbursement. Add in chemotherapy administration time-unit rules, drug wastage documentation, 340B eligibility tracking, and payer-specific step-therapy requirements, and the margin for error all but disappears.
QWay Healthcare provides oncology billing and coding services supported by certified oncology coders and physicians who understand the distinction between infusion, injection, and chemotherapy administration coding. Our team also tracks buy-and-bill economics and the documentation requirements that affect high-value oncology claims. Our AI-governed pre-submission validation flags missing NDC/J-code unit mismatches, incomplete wastage documentation, and expired or missing prior authorizations before a claim reaches the payer. Real-time denial monitoring identifies whether rejection spikes are tied to authorization gaps, drug-unit calculation errors, or medical necessity documentation, so your team can address the underlying cause instead of reworking the same denial type month after month.
The Financial Impact of Oncology Billing Variance
A mid-size oncology practice generating $12M in annual revenue, with drug costs representing the majority of that figure, operates on thin, drug-cost-exposed margins where billing errors are magnified.
Prior authorization gaps on chemotherapy, immunotherapy, and biologic infusions drive 18-24% of initial claim denials, representing $400K-$650K in delayed or lost annual revenue for a practice this size.
Chemotherapy administration and drug-unit coding errors — including J-code and NDC mismatches — add another 5-8% denial rate, exposing $180K-$300K annually.
Uncaptured or poorly documented drug wastage (JW/JZ modifier errors) quietly costs mid-size oncology practices $50K-$90K a year in reimbursement the practice already paid for but never billed.
Industry Benchmarks for Oncology Billing Performance
Stable, well-governed oncology organizations operate within these ranges:
Claim denial rate: under 10%
Clean claim rate on first submission: 85 to 92%
Prior authorization approval rate before treatment start: above 95%
Accounts receivable days: under 40
Drug wastage capture rate: above 97%
Where the Problem Starts
Prior authorization gaps on drug-based treatment.
Chemotherapy regimens, immunotherapy, and targeted biologics almost always require authorization before treatment begins, and approvals often carry visit-count or dosage limits that get exceeded mid-course without anyone flagging it. A single missed reauthorization on a multi-cycle regimen can turn months of treatment into an unpaid claim.
J-code, NDC, and unit-of-measure mismatches
Drug billing units don't always map cleanly to how a drug is packaged, dosed, or wasted. A vial-based drug billed in the wrong unit multiplier, or a J-code that doesn't match the NDC on the claim, is one of the most common — and most expensive — errors in oncology billing, since it affects a high-dollar line item rather than a routine visit code.
Incomplete drug wastage and administration documentation
When a single-use vial isn't fully administered, the unused portion is billable under separate wastage modifiers, but only when the discarded amount is clearly documented. Practices without a structured wastage-capture workflow routinely under-bill for drug they've already purchased and can never recover.
How QWay Healthcare Controls Oncology Billing and Coding
Prior authorization tracking across the full treatment course
We track authorization status, visit limits, and expiration dates across multi-cycle chemotherapy and immunotherapy regimens, flagging renewal needs before a scheduled infusion runs into an authorization gap.
J-code and NDC validation before submission
Our platform cross-checks billed units against NDC packaging and payer-specific unit rules, catching drug-unit mismatches before they become high-dollar denials.
Drug wastage capture governance
We enforce structured wastage documentation on every applicable claim, ensuring discarded drug amounts are captured with the JW/JZ modifier rather than written off.
Chemotherapy administration coding accuracy
We validate infusion, injection, and chemotherapy administration codes against documented start/stop times and route of administration, preventing under- or over-coding of administration services.
340B and buy-and-bill compliance monitoring
For practices operating under 340B, we track drug acquisition source and billing eligibility to prevent compliance exposure and recoupment risk.
Denial pattern analysis by drug and payer
Real-time monitoring identifies whether denial trends are concentrated in specific drugs, payers, or authorization types, so protocol fixes target the actual source rather than generic claim rework.
Revenue Exposure Categories Addressed
Prior Authorization Gaps
Gaps and lapses on chemotherapy and biologics.
J-Code & NDC Mismatches
Drug-unit mismatches between coding and packaging.
Incomplete Drug Wastage Documentation
Missing documentation on discarded drug amounts.
Time-Based Coding Errors
Chemotherapy administration and infusion coding errors.
340B & Buy-and-Bill Exposure
Compliance exposure across acquisition sources.
Multi-Payer Inconsistency
Step-therapy and medical necessity requirement gaps.
Talk to a Revenue Cycle Expert
See how AI-enabled revenue governance can stabilize reimbursement and reduce denials for your organization.
Request a Consultation